Table 3:
Concentration of palbociclib reached adequate tumor concentrations of > 0.06 uM
| Patient | Plasma (ng/mL) |
Plasma concentration |
Tumor (ng/g) |
Tumor concentration |
RB1 IHC (%) |
PFS (wks) |
OS (wks) |
|---|---|---|---|---|---|---|---|
| PD 107 | 52.2 ng/ml |
0.094 uM | 827 ng/g |
1.44 uM | 71.9 | 6.3 | 19.0 |
| PD 112 | 84.9 ng/ml |
0.148 uM | 2440 ng/g |
4.25 uM | 64.2 | 4.9 | 5.9 |
| PD 118 | 51.3 ng/ml |
0.089 uM | 1180 ng/g |
2.06 uM | 77.3 | 3.0 | 24.4 |
| PD 120 | 42.3 ng/ml |
0.074 uM | 144 ng/g |
0.25 uM | 89.9 | NA* | Unknown* |
| PD 121 | 50.4 ng/ml |
0.088 uM | 1910 ng/g |
3.33 nM | 83.0 | 2.4 | 56.0 |
*
Patient course complicated by post-op infection and did not receive post-op treatment and was lost to follow-up